MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
Exploring the companies and themes that make up this emerging and exciting new sector
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases, ‘Regardless Of The Amount’
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
Will ATAI IPO Be The First Major Psychedelics Catalyst For 2021?
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
Will psychedelic mushroom vacations come to the U. S.?
The palm-fringed beachfront and breezy cabanas at MycoMeditations are the stuff of glossy travel brochures, but the barefoot vacationers roaming the Jamaican retreat center this winter are seeking a different kind of trip entirely.
Further Research into Psilocybin Opens New Doors for Treatment
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others.
BetterLife Pharma forms psychedelic research advisory board and taps industry veteran Hattie Wells as its first member
BetterLife Pharma Inc tapped the experience of psychedelic pioneer Hattie Wells to join its new psychedelic research advisory board.
Mind Cure Tackles Mental Health Crisis On Two Fronts
Psychedelic Stock Watch connects the dots regarding Mind Cure's clinic launch and latest product development news.
Mind Cure Announces Build-Out of Digital Therapeutics,iSTRYM: A Technology Platform for Mental Wellness Optimization & PsychedelicResearch
Mind Cure's iSTRYM digital therapeutics platform is designed to provide real-time data regarding patient care.
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products
Numinus announces a product development agreement with Optimi Health Corp.
CYBIN Provides Update on Patent Filings & Development of Therapeutics Program
Cybin Corp updates investors on its IP development